RE: Multibag news1 Feb 2026 10:15
fair point cautious , certainly wouldn’t argue with that but they do mention phase 2 development again in the phase 1 close rns , post kirkstall , albeit no mention of ambitious funding . by themselves .
obvious still value in the ip and orphan designation but unless we see some movement with ib tech going to be a looooooong hold .
i’m interested now to see if ib zero gets developed . game changer or bull****.
with phase 1 now complete, ib is actively engaging with leading cancer centers to initiate a phase 2 trial aimed at further evaluating gam's efficacy and expanding its clinical footprint.